AGL (28) SHC (53) DVA (77) VMD (69) ⌘ Pro Terminal →

Progyny Inc. (PGNY) — RQD Stock Rating Cockpit

$28.40 +1.90% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Progyny Inc. (PGNY) earns a Roarable Rating of B+ (Buy) with 77/100 RQD Confidence. High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B+ • BUY Cap $2.18B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B+

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B+ · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+8.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PGNY)Realized 20D OHLCV Swing Band: ±7.4%

RSI-14 MOMENTUMBULLISH MOMENTUM

6230 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

8.84>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE72% OF RANGE

L: $16$28.40H: $33

1. Money & Cash Health● HEALTHY

Are profits real cash in the bank?

Real cash coming in backs up reported profits (24% profit margin and healthy balance-sheet cushion).

Factor Grade: A-RQD 17 / 20

2. Big Money & Insiders● BUYING

Are whales & executives buying or selling?

Hedge funds and options traders are leaning bullish, showing strong institutional appetite.

Factor Grade: BRQD 29 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B+RQD 31 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bullish on PGNY

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BULLISH (85)

16.7% ROIC with 23.6% gross margin and 8.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

BULLISH (75)

Altman-Z 8.84 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BULLISH (75)

29/40 institutional & smart-money positioning score with 16/20 macro alignment.

Bull Case: Why Buyers Like PGNY

✓Strong cash generator (24% profit margin)—profits are backed by real money, not accounting tricks.
✓Company leadership has skin in the game with net positive insider conviction.
✓Clean SEC annual filing review with no major hidden accounting time-bombs.

Bear Case: What Could Go Wrong

!Broader market pullbacks can still drag down strong stocks in the short run.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PGNY Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

PGNY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +52.85%⚡ TESTING RESISTANCE

2026-10-30O $28.66H $29.22L $28.30C $28.40VOL 807.7K

RES: $29.04SUP: $23.84SMA50: $26.88SMA200: $24.36

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PGNY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PGNY Butterfly Map → + Track PGNY →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

28.5%/yr Implied 5Y Growth

vs. +10.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on PGNY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PGNY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for PGNY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PGNY)

Health Care Rank #29 of 1016 ⚔️ AGL vs PGNY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PGNY vs. AGL, SHC, DVA, VMD)

Industry: Misc Health and Biotechnology Services (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Progyny Inc. (PGNY) ranks #29 by composite RQD confidence (77/100, grade B+) and #248 by equity capitalization ($2.18B). Within this direct 5-issuer industry benchmark cohort, DVA leads on earnings valuation at 11.4x trailing P/E, while DVA leads on capital efficiency and profitability with 29.2% ROIC and — gross margin. PGNY currently leads its immediate peer cohort in composite quantitative strength at 77/100 (B+).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
PGNY ACTIVE Progyny Inc.	B+	77/100	37.2x	23.6%	16.7%	+1.90%	$2.18B	Benchmark Subject
AGL agilon health inc.	E	28/100	—	—	-35.0%	-5.56%	$1.44B	/agl-vs-pgny →
SHC Sotera Health Company	D+	53/100	68.5x	55.5%	3.1%	+0.27%	$5.34B	/shc-vs-pgny →
DVA DaVita Inc.	B+	77/100	11.4x	—	29.2%	+5.10%	$12.33B	/dva-vs-pgny →
VMD Viemed Healthcare Inc.	C+	69/100	24.6x	57.5%	13.0%	-0.40%	$379.0M	/vmd-vs-pgny →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001551306

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Progyny Inc. (PGNY) reported GAAP revenue of $1.29B (+10.4% vs. FY2024 revenue of $1.17B , and +18.4% cumulative change since FY2023) , GAAP net income of $58.5M, operating cash flow of $210.2M, and free cash flow of $191.8M (+10.4% YoY). On the balance sheet, PGNY closed FY2025 with $742.4M in total assets against $0 in total debt (Altman Z-Score: 8.84, Piotroski F-Score: 7/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.29B	$58.5M	$210.2M	$191.8M	$742.4M	—
FY2024 (FY)	2024-12-31	$1.17B	$54.3M	$179.1M	$173.7M	$607.1M	—
FY2023 (FY)	2023-12-31	$1.09B	$62.0M	$188.8M	$188.8M	—	—

3. PGNY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PGNY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Progyny Inc. (NASDAQ: PGNY) is rated B+ (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 77/100 at a spot price of $28.40 (+1.90% 1D, market cap $2.18B). Pillar breakdown: Fundamental Cash Engine 17/20, Institutional 13F & Options Flow 13/20, Executive Insider Alignment 15/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 16/20. Across 1016 tracked Health Care issuers, PGNY ranks #29 in composite RQD confidence.

How does PGNY compare to AGL and SHC in the Health Care sector?

Within the Health Care sector (Misc Health and Biotechnology Services), PGNY carries a Roarable B+ (77/100 RQD), trailing P/E of 37.2x, gross margin of 23.6%, and ROIC of 16.7%. By comparison, AGL (agilon health inc.) holds a E grade (28/100 RQD, P/E N/A, ROIC -35.0%, cap $1.44B) and SHC (Sotera Health Company) posts a D+ grade (53/100 RQD, P/E 68.5x, ROIC 3.1%, cap $5.34B). Among the 5-stock peer group, DVA leads on earnings multiple (11.4x) while DVA leads on capital efficiency (29.2% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PGNY?

Per PGNY's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001551306), Progyny Inc. generated $1.29B in revenue (+10.4% YoY), $58.5M in net income, and $191.8M in free cash flow against $742.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (24% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PGNY trading relative to its 50-day, 200-day, and 52-week technical levels?

PGNY last traded at $28.40 (+1.90% on volume of 657,499 shares), positioning the stock +5.65% above its 50-day simple moving average ($26.88) and +16.58% above its 200-day simple moving average ($24.36). Across its 52-week range of $16.10 to $33.07, PGNY sits at the 72.5% percentile with a 14-day RSI of 62.0 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.4% ($26.30 to $30.50).

PGNY Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell PGNY stock right now?

Progyny Inc. (PGNY) currently earns a Roarable Rating of B+ (Buy — BUY) with 77/100 RQD Confidence. High-quality cash engine (24% profit margin, 17% return on capital) with steady institutional support.

What is PGNY's 12-month price target and RQD AI Jury consensus?

PGNY's 12-month base price target is $30.83 (range $23.29 to $36.38), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: PGNY RQD Cockpit PGNY 12M Forecast PGNY Earnings & Move PGNY Dividends & DRIP PGNY Insiders & 13F PGNY Whale Options PGNY Profit Sankey PGNY News & Why